U.S. markets close in 3 hours 58 minutes

VectivBio Holding AG (VECT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
5.75+0.24 (+4.31%)
As of 10:24AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close5.51
Bid5.51 x 800
Ask5.83 x 800
Day's Range5.62 - 5.75
52 Week Range2.74 - 8.90
Avg. Volume22,741
Market Cap257.262M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.23
Earnings DateApr 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VECT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • VectivBio Holding AG
    Daily – Vickers Top Buyers & Sellers for 07/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    16 days agoArgus Research
View more
  • GlobeNewswire

    Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

    $5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update. High

  • GlobeNewswire

    VectivBio Announces Closing of $54 Million Aggregate Financing

    BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters’ previously granted option to purchase additional or

  • GlobeNewswire

    VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

    Combined Gross Proceeds from Public Offering and Private Sale Total $50 MillionBASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offering of 5,715,000 ordinary shares at a public offering price of $5.25 per share for aggregate gross proceeds of approximately $30 million, before